0 false false false false false false false false false false true false false false false false false No description of principal activity 2024-11-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 11633388 2024-11-01 2025-10-31 11633388 2025-10-31 11633388 2024-10-31 11633388 2023-11-01 2024-10-31 11633388 2024-10-31 11633388 2023-10-31 11633388 core:LandBuildings core:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 11633388 core:PlantMachinery 2024-11-01 2025-10-31 11633388 core:FurnitureFittings 2024-11-01 2025-10-31 11633388 bus:LeadAgentIfApplicable 2024-11-01 2025-10-31 11633388 bus:Director1 2024-11-01 2025-10-31 11633388 bus:Director2 2024-11-01 2025-10-31 11633388 core:WithinOneYear 2025-10-31 11633388 core:WithinOneYear 2024-10-31 11633388 core:AfterOneYear 2025-10-31 11633388 core:AfterOneYear 2024-10-31 11633388 core:ShareCapital 2025-10-31 11633388 core:ShareCapital 2024-10-31 11633388 core:RetainedEarningsAccumulatedLosses 2025-10-31 11633388 core:RetainedEarningsAccumulatedLosses 2024-10-31 11633388 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 11633388 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-10-31 11633388 core:CostValuation core:Non-currentFinancialInstruments 2025-10-31 11633388 core:Non-currentFinancialInstruments 2025-10-31 11633388 core:Non-currentFinancialInstruments 2024-10-31 11633388 bus:SmallEntities 2024-11-01 2025-10-31 11633388 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 11633388 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 11633388 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 11633388 bus:AbridgedAccounts 2024-11-01 2025-10-31
COMPANY REGISTRATION NUMBER: 11633388

Chlobex Limited

Filleted Unaudited Abridged Financial Statements

31 October 2025

Chlobex Limited

Abridged Financial Statements

Year ended 31 October 2025

Contents | Page

Chartered accountant's report to the board of directors on the preparation of the unaudited statutory abridged financial statements | 1

Abridged statement of financial position | 2

Notes to the abridged financial statements | 4

Chlobex Limited

Chartered Accountant's Report to the Board of Directors on the Preparation of the Unaudited Statutory Abridged Financial Statements of Chlobex Limited

Year ended 31 October 2025
As described on the abridged statement of financial position, the directors of the company are responsible for the preparation of the abridged financial statements for the year ended 31 October 2025, which comprise the abridged statement of financial position and the related notes. You consider that the company is exempt from an audit under the Companies Act 2006. In accordance with your instructions we have compiled these abridged financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.
HARPER SHELDON LIMITED Chartered accountants
Midway House Staverton Technology Park Herrick Way, Staverton Cheltenham, Glos. GL51 6TQ
20 July 2026

Chlobex Limited

Abridged Statement of Financial Position

31 October 2025

| 2025 | 2024
Note | £ | £

Fixed assets

Tangible assets | 4 | 851,399 | 881,406
Investments | 5 | 205,207 | 198,207
| ------------ | ------------
| 1,056,606 | 1,079,613

Current assets

Debtors | 1,724 | 1,716
Cash at bank and in hand | 6,154 | 980
| ------- | -------
| 7,878 | 2,696

Creditors: amounts falling due within one year | 707,658 | 704,983
| --------- | ---------
Net current liabilities | 699,780 | 702,287
| ------------ | ------------
Total assets less current liabilities | 356,826 | 377,326

Creditors: amounts falling due after more than one year | 336,456 | 368,416
| --------- | ---------
Net assets | 20,370 | 8,910
| --------- | ---------

Capital and reserves

Called up share capital | 10,100 | 10,100
Profit and loss account | 10,270 | ( 1,190)
| -------- | --------
Shareholders funds | 20,370 | 8,910
| -------- | --------

These abridged financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of income and retained earnings has not been delivered.
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .
All of the members have consented to the preparation of the abridged statement of income and retained earnings and the abridged statement of financial position for the year ending 31 October 2025 in accordance with Section 444(2A) of the Companies Act 2006.

Chlobex Limited

Abridged Statement of Financial Position (continued)

31 October 2025
These abridged financial statements were approved by the board of directors and authorised for issue on 20 July 2026 , and are signed on behalf of the board by:

Mrs C D Dyer | Mr R P Dyer
Director | Director

Company registration number: 11633388

Chlobex Limited

Notes to the Abridged Financial Statements

Year ended 31 October 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 4 Bristol Road, Stonehouse, Gloucestershire, GL10 2BQ.
2. Statement of compliance
These abridged financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The abridged financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The abridged financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Freehold property | - | 2% straight line
| Freehold improvements | - | 10% straight line
| Fixtures and fittings | - | 25% straight line

Investment property
Investment property was valued at the balance sheet date by the director on an open market basis. The director determined that the fair value was not materially different to historic cost.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
4. Tangible assets

| £
Cost |
At 1 November 2024 | 1,021,225
Additions | 6,869
| ------------
At 31 October 2025 | 1,028,094
| ------------
Depreciation |
At 1 November 2024 | 139,819
Charge for the year | 36,876
| ------------
At 31 October 2025 | 176,695
| ------------
Carrying amount |
At 31 October 2025 | 851,399
| ------------
At 31 October 2024 | 881,406
| ------------

Investment property was valued at the balance sheet date by the director on an open market basis. The director determined that the fair value was not materially different to historic cost.
5. Investments

| £
Cost |
At 1 November 2024 | 198,207
Additions | 7,000
| ---------
At 31 October 2025 | 205,207
| ---------
Impairment |
At 1 November 2024 and 31 October 2025 | –
| ---------
Carrying amount |
At 31 October 2025 | 205,207
| ---------
At 31 October 2024 | 198,207
| ---------

6. Related party transactions
Carol Dyer and Richard Dyer are directors of Carich Care Ltd. At the year end Chlobex Ltd owe Carich Care £691,988 (2024: £691,962).